Results 91 to 100 of about 681,792 (231)

Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations

npj Precision Oncology
Management of advanced hormone receptor-positive, HER2-negative breast cancer after progression on endocrine therapy plus CDK4/6 inhibitors is challenging due to mutational heterogeneity. Current therapies yield limited efficacy, achieving 4–6 months PFS.
Noelia Martinez-Jañez, José Ángel García-Saenz, Sonia Pernas, Begoña Bermejo, Serafín Morales, Juan Guerra, Jorge Silva, Luis Manso, Eva Ciruelos, Pablo Tolosa, Rodrigo Sánchez-Bayona, Manuel Alva, Silvia Calabuig-Fariñas, Sandra Gallach, Laura Muinelo-Romay, Elena Piñeiro-Yáñez, Eduardo Caleiras, Maria J. Bueno, Silvana Mouron, Miguel Quintela-Fandino   +19 more
doaj   +1 more source

Smart mesoporous silica nanoparticles for precision cancer therapy: Tumor targeting and stimuli‐responsive controlled release

Smart Molecules, EarlyView.
Smart mesoporous silica nanoparticles integrate tunable pore structures, molecular gates, targeting ligands, and stimuli‐responsive components to achieve controlled drug release for precision cancer therapy. This review highlights design principles, therapeutic applications, and future directions in immunotherapy, biodegradability, biosafety, and ...
Majdi Al‐Amili, Lei Lei, Zhu Jin
wiley   +1 more source

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines

Frontiers in Oncology, 2019
Fibroblast Growth Factor Receptors (FGFR1–4) have a critical role in the progression of several human cancers, including Squamous Non-Small-Cell Lung Cancer (SQCLC).
Claudia Fumarola, Nicole Bozza, Riccardo Castelli, Francesca Ferlenghi, Giuseppe Marseglia, Alessio Lodola, Mara Bonelli, Silvia La Monica, Daniele Cretella, Roberta Alfieri, Roberta Minari, Maricla Galetti, Maricla Galetti, Marcello Tiseo, Marcello Tiseo, Andrea Ardizzoni, Marco Mor, Pier Giorgio Petronini   +17 more
doaj   +1 more source

Australian Practical Guide on the Management of Muscle‐Invasive Bladder Cancer

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Australia's management of muscle‐invasive bladder cancer is evolving, with increased use of perioperative therapy and emerging immunotherapies. However, challenges such as cisplatin ineligibility, limited access, and costs persist. Expanding bladder‐sparing approaches, precision medicine, and integrated care pathways will be key to improving outcomes ...
Dickon Hayne, Shomik Sengupta, Alison Y. Zhang, Niara Oliveira, Manish I. Patel, Ian Vela, Ian D. Davis   +6 more
wiley   +1 more source

Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells

Breast Cancer Research
Fibroblast growth factors (FGFs) control various cellular functions through fibroblast growth factor receptor (FGFR) activation, including proliferation, differentiation, migration, and survival.
Feng Chi, Jason I. Griffiths, Aritro Nath, Andrea H. Bild   +3 more
doaj   +1 more source

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

Andrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis, Lisa Schneider, Felix Bremmer, Daniel Nettersheim   +3 more
wiley   +1 more source

Fibroblast growth receptor 1 is regulated by G-quadruplex in metastatic breast cancer

Communications Biology
Limiting cellular plasticity is of key importance for the therapeutic targeting of metastatic breast cancer (MBC). Fibroblast growth receptor (FGFR) is a critical molecule in cellular plasticity and potent inhibitors of FGFR enzymatic activity have been ...
Hang Lin, Muhammad Hassan Safdar, Sarah Washburn, Saeed S. Akhand, Jonathan Dickerhoff, Mitchell Ayers, Marvis Monteiro, Luis Solorio, Danzhou Yang, Michael K. Wendt   +9 more
doaj   +1 more source

PTEN homozygous deletion is a negative prognostic factor in tumor treating fields‐treated glioblastoma, IDH wildtype patients

Brain Pathology, EarlyView.
In a molecularly confirmed cohort of 64 newly diagnosed, TTFields‐treated glioblastomas, IDH‐wildtype, homozygous PTEN deletion was associated with markedly shorter overall survival (368 vs. 603 days) and remained an independent adverse prognostic factor.
Jakob Nückles, Claudius Jelgersma, Christin Siewert, Brendan Osberg, Simone Schmid, Arend Koch, Eilís Perez, Daniel Teichmann, Martin Misch, Anna‐Gila Karbe, Susanne Ukrow, Patrick N. Harter, Ruth M. Stassart, Peter Vajkoczy, Julia Onken, David Capper   +15 more
wiley   +1 more source

Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer

Cancer Science, EarlyView.
Integrated analysis of 445 bladder cancers showed that HER2 membrane expression and ERBB2 amplification are distinct features. HER2 expression overlapped with NECTIN4 expression, whereas ERBB2 amplification was enriched in the LumU subtype and associated with poor prognosis.
Kensuke Hirosuna, Kazuki Nishimura, Moritoshi Sakamoto, Satoshi Tokushige, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Takeshi Tsutsumi, Ryoichi Maenosono, Takuya Tsujino, Masahiko Ajiro, Haruhito Azuma, Akihide Yoshimi, Kazumasa Komura   +13 more
wiley   +1 more source

Fibroblast Growth Factor Receptor Signaling in Skin Cancers

Cells, 2019
Fibroblast growth factor (FGF)/Fibroblast growth factor receptor (FGFR) signaling regulates various cellular processes during the embryonic development and in the adult organism.
Malgorzata Czyz
doaj   +1 more source